taVNS in Mild to Moderate Parkinson's Disease

Medical University of South Carolina33 enrolled

Overview

The purpose of this study is to find out whether a non-invasive form of nerve stimulation called transcutaneous vagus nerve stimulation (taVNS) is safe and effective in people with Parkinson's Disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Parkinson Disease

Interventions

Active taVNSDEVICE

Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus

Sham StimulationDEVICE

Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age: 40-79 y * Idiopathic Parkinson's Disease Diagnosis * Disease Stage: Hoehn and Yahr stage 2-3 * Patient requires a minimum of 3 doses of levodopa daily * Willingness to be videotaped Exclusion criteria: * Dementia or Montreal Cognitive Assessment score \<24 * Parkinson's Disease psychosis * Ear trauma * Facial pain * Traumatic Brain Injury or clinical history of stroke * Metal implants above the shoulders * History of myocardial infarction or arrhythmia, bradycardia * Active respiratory disorder * Alcohol or substance use disorders * History of Deep Brain Stimulation (DBS) or other brain surgery * Epilepsy * Pregnancy * B-Blockers, dopamine blocking agent, antiarrhythmic medication, acetylcholine esterase inhibitor, midodrine, florinef, droxidopa, or anticholinergic drugs

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States

Outcomes

Primary Outcomes

Change in Motor Function Score as Assessed by Modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III

The MDS-UPDRS is a rating scale used in research and clinic to rate the severity of Parkinson's Disease. A low score indicates mild disease and a high score more advanced disease. The possible range for MDS-UPDRS Part III is 0-132. Higher scores reflect greater motor disturbance. A decline in score from pre-post would indicate improvement. This outcome observed Part III of UPDRS motor examination. Information on cover page: The MDS-UPDRS has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination) and Part IV (motor complications). Part I has two components: IA concerns a number of behaviors that are assessed by the investigator with all pertinent information from patients and caregivers, and IB is completed by the patient with or without the aid of the caregiver, but independently of the investigator. These sections can, however, be reviewed by the rater to ensure that all questions are answered clea

Time frame: Baseline (Visit 1) to Day 14 (Visit 10)

Secondary Outcomes

Change in Cognitive Function Score

Delis-Kaplan Executive Function System (DKEFS) letter fluency is an investigator administered test that assesses verbal fluency. Higher scores indicate more correct responses. A positive value of change means an improvement in fluency. A decrease in score represents decrease in fluency. The minimum score is 0 and there is no maximum score. The raw score is total from letters F, A, and S.

Time frame: Screening to Day 13 (Visit 9)

Change in Cognitive Function Score

DKEFS category fluency is an investigator administered test checking into ability to switch between categories presented. There is no upper limit on the D-KEFS measures. There is no lower limit on the D-KEPS measure. Higher scores reflect better verbal fluency. An increase in score from pre-post would indicate improvement. Decrease in value represents decrease in fluency. Raw score is total of Animals + Boys Names.

Time frame: Screening to Day 13 (Visit 9)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.